Isomaltooligosaccharide testing: what breath gases can tell you

A breath test for an ingredient sold as fiber

Isomaltooligosaccharides, usually shortened to IMO, appear in some bars, syrups and shakes. Products can differ in their composition and digestibility, so calling a mixture “prebiotic fiber” does not necessarily tell the whole story.

One proposed approach to an IMO breath challenge works like this: after preparation and a measured IMO solution, you provide breath samples over roughly two to three hours. The samples are tested for hydrogen and methane, measured in parts per million, or ppm. These gases can arise when microbes process carbohydrates that have not been fully absorbed, and can be detected in exhaled air. A symptom diary records bloating, pain or an urge to have a bowel movement.

The distinction that matters is the protocol. An IMO challenge is not interchangeable with established breath tests using other substances. The dose, validated cutoffs and clinical usefulness need to be established for that specific procedure. An IMO challenge cannot currently be described as a generally accepted routine test.

Why you might want to understand your IMO tolerance

Bloating after a new protein bar or “high-fiber” product can have several explanations. IMO is only one possible ingredient involved. Portion size, other sugar alcohols or fermentable ingredients, and your own gut sensitivity all matter.

Microbial fermentation can produce useful metabolites as well as gas. A larger rise in breath gases is not automatically harmful, and a smaller rise is not automatically healthy. Symptoms and the conditions of the test give the numbers their meaning.

Changes in training, diet, antibiotic use or GLP-1-based medicines may form part of the background to testing. Changes in stomach emptying and intestinal transit can affect a breath curve. But the result does not explain general skin, mood or metabolic problems. A close look at the product label, portion and timing of symptoms is often a more useful starting point.

Reading a fermentation curve

A report may show baseline readings followed by repeated hydrogen and methane measurements over 120 to 180 minutes. Some interpretations refer to a hydrogen rise of at least 20 ppm or an early rise within 60 to 90 minutes. Those numbers come from other breath-testing frameworks. They should not be adopted as universal diagnostic cutoffs for an IMO challenge without validation.

An early rise can be affected by several factors, including transit time and preparation. It does not, by itself, prove small intestinal bacterial overgrowth. Methane also needs to be interpreted within the appropriate standardized protocol. It can be associated with constipation and slower transit, but it is not a simple measure of “gut balance.”

A small, later rise with few symptoms may be consistent with tolerating the tested dose. It cannot establish the condition of the intestinal barrier, inflammation levels or actual butyrate production. An unusually pronounced curve does not diagnose a disease either, especially when the mixture and dose are unclear.

IMO syrups vary in the proportion of readily digestible carbohydrates they contain. Some may therefore behave more like available carbohydrate than broad fiber claims suggest. The ingredient list and the specific product formulation are essential to interpreting the response.

What can distort the curve

Antibiotics, bowel preparation, diarrhea, constipation and changes in transit time can influence the response. Smoking, vigorous exercise and departures from the preparation instructions can also interfere. Follow the testing laboratory’s instructions, and do not change medicines or oral hygiene on your own.

People do not all produce the same amount of hydrogen. Other microbes can consume it, including through methane production. A low hydrogen curve therefore does not rule out fermentation. Measuring several gases together may add information, but it does not solve every interpretation problem.

For children and during pregnancy, the decision to test and the protocol need professional assessment. Collecting a breath sample is noninvasive; that does not mean every challenge or cutoff is appropriate. The test also does not sequence the microbiome or measure inflammation.

Where this approach may help and where it cannot

Under clearly defined conditions, a challenge can document gas production and symptoms in response to a particular product. Whether that leads to better long-term dietary decisions depends on the protocol and the question being asked. It does not provide a universal IMO tolerance score or a basis for routine repeat testing.

For persistent symptoms, other diagnostic steps may be more useful. Thoughtful dietary advice can help identify troublesome products and portions without unnecessarily avoiding all fiber.

Frequently asked questions

What does an isomaltooligosaccharide test measure?

The procedure described here measures breath hydrogen and methane after an IMO challenge. It does not measure IMO directly in the blood or produce a microbiome DNA profile. A provider should explain the test substance, dose, sampling period and validation.

How are samples collected?

After the required preparation, you drink a test solution and provide several breath samples at set intervals. A stool profile, if offered alongside it, is a different investigation with its own uses and limitations.

What does the result say about health?

It can show a gas response and symptoms during a particular challenge. It does not prove general food intolerance or an inflammatory disease. Having no symptoms during the test also does not guarantee that you will tolerate every product containing IMO.

How reliable is the test?

Reliability depends on standardization, preparation, dose, measurement quality and clinically validated interpretation criteria. A nonstandardized IMO protocol cannot simply borrow cutoffs from other breath tests. Without those details, a number is difficult to interpret.

How often should testing be repeated?

There is no general routine recommendation here. Before repeating a test, identify the new question it would answer and whether a product and symptom diary would be enough. Regular testing solely for “optimization” has no established clinical benefit.

Can the response change quickly?

Yes. Diet, medicines, transit time and temporary illness can shift the result. IMO itself is not a microbial population, so a change in the breath curve should not be described as a direct change in a particular bacterial species.

Does the test provide a diagnosis?

An isolated IMO curve does not establish a diagnosis. In particular, isomaltooligosaccharides as a test substance should not be confused with intestinal methanogen overgrowth, which is also abbreviated IMO. Diagnostic questions require the appropriate standardized procedure.

What can I do after an unusual result?

Start with the portion, ingredients and timing of symptoms. A smaller amount or a different product you tolerate may make more sense than a broadly low-fiber diet. This kind of curve is not a basis for choosing probiotics or antibiotics. Persistent pain, diarrhea, constipation or weight loss calls for medical or dietetic assessment.

Sources

• Gourineni V, Stewart ML, Icoz D, Zimmer JP (2018). Gastrointestinal tolerance and glycemic response of isomaltooligosaccharides in healthy adults. Nutrients, 10(3), 301. https://doi.org/10.3390/nu10030301 PubMed

• Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, Valdovinos M, Zakko S, Pimentel M (2017). Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American consensus. American Journal of Gastroenterology, 112(5), 775-784. https://doi.org/10.1038/ajg.2017.46 PubMed

• Mann ER, Lam YK, Uhlig HH (2024). Short-chain fatty acids: Linking diet, the microbiome and immunity. Nature Reviews Immunology, 24(8), 577-595. https://doi.org/10.1038/s41577-024-01014-8 PubMed

• Lynch SV, Pedersen O (2016). The human intestinal microbiome in health and disease. New England Journal of Medicine, 375(24), 2369-2379. https://doi.org/10.1056/NEJMra1600266 PubMed

• Allaband C, McDonald D, Vázquez-Baeza Y, Minich JJ, Tripathi A, Brenner DA, Loomba R, Smarr L, Sandborn WJ, Schnabl B, Dorrestein P, Zarrinpar A, Knight R (2019). Microbiome 101: Studying, analyzing, and interpreting gut microbiome data for clinicians. Clinical Gastroenterology and Hepatology, 17(2), 218-230. https://doi.org/10.1016/j.cgh.2018.09.017 PubMed